Furthermore, our study, the first to explore and compare the expression profile of this new immune checkpoint in paired primary and metastatic tumors of mCRC patients, demonstrates that HLA-E/β2m is preferentially expressed by tumor cells in metastases compared with primary tumors. Here, HLA-E is linked to metastatic neoplasm.